The stock of Eli Lilly and Company LLY has declined 1.7% already this week, losing almost $14 billion of its market value.

Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.

Pharmacists can continue making compounded versions of generic tirzepatide, the active ingredient in popular medications ...

On October 7, a compounding trade group filed a lawsuit challenging the agency's action, saying there was still a shortage of ...

The Food and Drug Administration said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of tirzepatide — the active ingredient in Eli Lilly’s ...

If the FDA were to eventually remove the drug from the shortage list, this would have significant implications for people using tirzepatide or compounded versions of the drugs. Is tirzepatide ...

Pharmacists may continue making compounded versions of the weight-loss medication tirzepatide while the U.S. Food and Drug Administration revisits its Oct. 2 decision to remove the medicine from a ...

The FDA said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of ...

(The Hill) – Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no longer in shortage after nearly two years. Pharmacies that ...